DUKE CLINICAL RESEARCH INSTITUTE

Michael D. Kappelman from UNC receives $14.4 million from PCORI to study new treatment options for pediatric inflammatory bowel diseases (PIBD).

A randomized, controlled trial found that montelukast, a common asthma drug, does not speed recovery from mild to moderate COVID-19 symptoms.

A randomized, controlled trial found that montelukast did not reduce the duration of COVID-19 symptoms in outpatients with mild to moderate illness.